Survival in a real-world cohort of patients with transthyretin amyloid cardiomyopathy treated with tafamidis: an analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)
Background - In the pivotal Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT), tafamidis significantly reduced mortality rates, leading to its approval in many countries for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). Real-world evidence on survival in patients...
Gespeichert in:
| Hauptverfasser: | , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
March 2025
|
| In: |
Journal of cardiac failure
Year: 2025, Jahrgang: 31, Heft: 3, Pages: 525-533 |
| ISSN: | 1532-8414 |
| DOI: | 10.1016/j.cardfail.2024.06.003 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.cardfail.2024.06.003 Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S1071916424002227 
|
| Verfasserangaben: | Pablo Garcia-Pavia, MD, PhD, Arnt V. Kristen, MD, Brian Drachman, MD, Martin Carlsson, MS, Leslie Amass, PhD, Franca Stedile Angeli, MD, PhD, Mathew S. Maurer, MD, on behalf of TheTHAOS investigators |
MARC
| LEADER | 00000naa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1933545909 | ||
| 003 | DE-627 | ||
| 005 | 20250819121301.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 250819s2025 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.cardfail.2024.06.003 |2 doi | |
| 035 | |a (DE-627)1933545909 | ||
| 035 | |a (DE-599)KXP1933545909 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a García-Pavía, Pablo |e VerfasserIn |0 (DE-588)123969976X |0 (DE-627)1767751869 |4 aut | |
| 245 | 1 | 0 | |a Survival in a real-world cohort of patients with transthyretin amyloid cardiomyopathy treated with tafamidis |b an analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS) |c Pablo Garcia-Pavia, MD, PhD, Arnt V. Kristen, MD, Brian Drachman, MD, Martin Carlsson, MS, Leslie Amass, PhD, Franca Stedile Angeli, MD, PhD, Mathew S. Maurer, MD, on behalf of TheTHAOS investigators |
| 264 | 1 | |c March 2025 | |
| 300 | |b Illustrationen | ||
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online verfügbar: 21. Juni 2024, Artikelversion: 11. März 2025 | ||
| 500 | |a Gesehen am 19.08.2025 | ||
| 520 | |a Background - In the pivotal Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT), tafamidis significantly reduced mortality rates, leading to its approval in many countries for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). Real-world evidence on survival in patients with ATTR-CM following tafamidis treatment has not been extensively reported. - Methods and Results - The Transthyretin Amyloidosis Outcomes Survey (THAOS) was a longitudinal, observational, phase 4 study of patients with transthyretin amyloidosis and asymptomatic participants carrying pathogenic transthyretin variants. Patients from THAOS with a predominantly cardiac phenotype at enrollment were included, and survival was analyzed according to tafamidis treatment status (treated or untreated). Results are based on the completed THAOS dataset. In tafamidis-treated (n=587) and tafamidis-untreated (n=854) patients, respectively, median age at enrollment was 77.7 and 76.4 years, 91.8% and 90.0% were male, and 91.8% and 83.8% had wild-type disease. Survival rates (95% CI) at 30 and 42 months, respectively, were 84.4% (80.5-87.7) and 76.8% (70.9-81.7) in tafamidis-treated patients, and 70.0% (66.4-73.2) and 59.3% (55.2-63.0) in tafamidis-untreated patients. Survival rates in genotype subgroups (wild-type and variant) were similar to those of the overall cohort. Survival rates were better in a contemporary cohort, as reflected by a sensitivity analysis performed in patients enrolled after vs before 2019. No new safety signals were identified. - Conclusions - In this real-world cohort of patients with ATTR-CM, survival rates were higher than in ATTR-ACT and consistent with more recent reports, suggesting early diagnosis and treatment with tafamidis has improved life expectancy in ATTR-CM. These results provide further evidence supporting tafamidis’ safety and effectiveness. Trial registration: ClinicalTrials.gov identifier: NCT00628745 | ||
| 650 | 4 | |a real-world | |
| 650 | 4 | |a survival | |
| 650 | 4 | |a tafamidis | |
| 650 | 4 | |a Transthyretin amyloid cardiomyopathy | |
| 700 | 1 | |a Kristen, Arnt |d 1974- |e VerfasserIn |0 (DE-588)123480965 |0 (DE-627)706314530 |0 (DE-576)293726876 |4 aut | |
| 700 | 1 | |a Drachman, Brian |e VerfasserIn |4 aut | |
| 700 | 1 | |a Carlsson, Martin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Amass, Leslie |e VerfasserIn |4 aut | |
| 700 | 1 | |a Angeli, Franca Stedile |e VerfasserIn |4 aut | |
| 700 | 1 | |a Maurer, Mathew S. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of cardiac failure |d New York, NY : Elsevier, 1994 |g 31(2025), 3 vom: März, Seite 525-533 |h Online-Ressource |w (DE-627)330078410 |w (DE-600)2048826-9 |w (DE-576)264629159 |x 1532-8414 |7 nnas |a Survival in a real-world cohort of patients with transthyretin amyloid cardiomyopathy treated with tafamidis an analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS) |
| 773 | 1 | 8 | |g volume:31 |g year:2025 |g number:3 |g month:03 |g pages:525-533 |g extent:9 |a Survival in a real-world cohort of patients with transthyretin amyloid cardiomyopathy treated with tafamidis an analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS) |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.cardfail.2024.06.003 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S1071916424002227 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20250819 | ||
| 993 | |a Article | ||
| 994 | |a 2025 | ||
| 998 | |g 123480965 |a Kristen, Arnt |m 123480965:Kristen, Arnt |d 910000 |d 910100 |d 50000 |e 910000PK123480965 |e 910100PK123480965 |e 50000PK123480965 |k 0/910000/ |k 1/910000/910100/ |k 0/50000/ |p 2 | ||
| 999 | |a KXP-PPN1933545909 |e 4758947686 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"recId":"1933545909","note":["Online verfügbar: 21. Juni 2024, Artikelversion: 11. März 2025","Gesehen am 19.08.2025"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"title":[{"subtitle":"an analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)","title":"Survival in a real-world cohort of patients with transthyretin amyloid cardiomyopathy treated with tafamidis","title_sort":"Survival in a real-world cohort of patients with transthyretin amyloid cardiomyopathy treated with tafamidis"}],"language":["eng"],"person":[{"family":"García-Pavía","display":"García-Pavía, Pablo","roleDisplay":"VerfasserIn","role":"aut","given":"Pablo"},{"family":"Kristen","given":"Arnt","role":"aut","roleDisplay":"VerfasserIn","display":"Kristen, Arnt"},{"family":"Drachman","given":"Brian","roleDisplay":"VerfasserIn","role":"aut","display":"Drachman, Brian"},{"display":"Carlsson, Martin","given":"Martin","role":"aut","roleDisplay":"VerfasserIn","family":"Carlsson"},{"display":"Amass, Leslie","given":"Leslie","role":"aut","roleDisplay":"VerfasserIn","family":"Amass"},{"display":"Angeli, Franca Stedile","given":"Franca Stedile","roleDisplay":"VerfasserIn","role":"aut","family":"Angeli"},{"display":"Maurer, Mathew S.","given":"Mathew S.","role":"aut","roleDisplay":"VerfasserIn","family":"Maurer"}],"relHost":[{"origin":[{"publisherPlace":"New York, NY ; London ; New York","dateIssuedKey":"1994","dateIssuedDisp":"1994-","publisher":"Elsevier ; Harcourt ; Churchill Livingstone"}],"physDesc":[{"extent":"Online-Ressource"}],"language":["eng"],"disp":"Survival in a real-world cohort of patients with transthyretin amyloid cardiomyopathy treated with tafamidis an analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)Journal of cardiac failure","title":[{"subtitle":"official journal of the Heart Failure Society of America and the Japanese Heart Failure Society","title_sort":"Journal of cardiac failure","title":"Journal of cardiac failure"}],"pubHistory":["1.1994 -"],"type":{"media":"Online-Ressource","bibl":"periodical"},"part":{"extent":"9","year":"2025","pages":"525-533","text":"31(2025), 3 vom: März, Seite 525-533","issue":"3","volume":"31"},"recId":"330078410","note":["Gesehen am 25.10.21"],"id":{"eki":["330078410"],"zdb":["2048826-9"],"issn":["1532-8414"]}}],"name":{"displayForm":["Pablo Garcia-Pavia, MD, PhD, Arnt V. Kristen, MD, Brian Drachman, MD, Martin Carlsson, MS, Leslie Amass, PhD, Franca Stedile Angeli, MD, PhD, Mathew S. Maurer, MD, on behalf of TheTHAOS investigators"]},"origin":[{"dateIssuedDisp":"March 2025","dateIssuedKey":"2025"}],"id":{"doi":["10.1016/j.cardfail.2024.06.003"],"eki":["1933545909"]},"physDesc":[{"noteIll":"Illustrationen","extent":"9 S."}]} | ||
| SRT | |a GARCIAPAVISURVIVALIN2025 | ||